Last reviewed · How we verify

Helse Nord-Trøndelag HF — Portfolio Competitive Intelligence Brief

Helse Nord-Trøndelag HF pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Isotone saline water Isotone saline water phase 3 Crystalloid fluid / Electrolyte solution Critical Care / Fluid Management
Botulinum Toxin Type A in saline water Botulinum Toxin Type A in saline water phase 3 Neurotoxin; Acetylcholine release inhibitor SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Movement Disorders; Aesthetics

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centre Hospitalier Universitaire de Nice · 1 shared drug class
  2. Croma-Pharma GmbH · 1 shared drug class
  3. Daniel Hägi-Pedersen · 1 shared drug class
  4. EvergreenHealth · 1 shared drug class
  5. Hennepin Healthcare Research Institute · 1 shared drug class
  6. IRCCS Burlo Garofolo · 1 shared drug class
  7. Meshalkin Research Institute of Pathology of Circulation · 1 shared drug class
  8. Ministry of Health, Spain · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Helse Nord-Trøndelag HF:

Cite this brief

Drug Landscape (2026). Helse Nord-Trøndelag HF — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/helse-nord-tr-ndelag-hf. Accessed 2026-05-17.

Related